ASH 2010 meeting report-Top 10 clinically-oriented abstracts in myelodysplastic syndromes (MDS)

Abstract

The December 2010 American Society of Hematology (ASH) annual meeting in Orlando, Florida included more than 150 abstracts in the myelodysplastic syndromes (MDS) category. Thirty-six MDS-focused abstracts were presented in 6 oral sessions, and 120 additional abstracts were presented in 3 poster sessions. Although the 2010 ASH annual meeting included relatively little new MDS clinical trial data, with only one large randomized trial presented (the Intergroup E1905 study), it was an exciting conference from the standpoint of molecular discoveries in myeloid neoplasms, as various investigative groups presented results offering novel insights into MDS pathobiology, generated via high-throughput genomic sequencing and other innovative laboratory techniques. Here I summarize and discuss 10 MDS-related abstracts of special interest, which contain information that informs clinical practice. All 10 of these abstracts are published in full in the November 19, 2010 issue of Blood (volume 116, issue 21) and are identified here by their abstract number and title. © 2011 Wiley-Liss, Inc.